| 王 婷,马惠文,王东林,李代蓉,余慧青,王思雄,王恩文.EGFR基因21外显子L858R突变肺腺癌患者化疗和靶向治疗疗效的对比研究[J].,2018,(2):348-351 |
| EGFR基因21外显子L858R突变肺腺癌患者化疗和靶向治疗疗效的对比研究 |
| A Comparative Study on the Clinical Efficacy of Chemotherapy and Targeted Therapy for Lung Adenocarcinoma Patients with EGFR Gene 21 Exon L858R Mutation |
| 投稿时间：2017-06-06 修订日期：2017-06-30 |
| DOI：10.13241/j.cnki.pmb.2018.02.034 |
| 中文关键词: EGFR基因 基因突变 肺腺癌 临床疗效 |
| 英文关键词: EGFR gene Gene mutation Lung adenocarcinoma Clinical efficacy |
| 基金项目:中国癌症基金会北京希望马拉松专项资金资助（LC2016W04） |
|
| 摘要点击次数: 746 |
| 全文下载次数: 550 |
| 中文摘要: |
| 摘要 目的：研究化疗和靶向治疗对EGFR基因21外显子L858R突变肺腺癌患者的临床疗效和患者生存率的影响。方法：选择2012年1月~2016年1月在重庆市肿瘤医院治疗的95例EGFR基因21外显子L858R突变的肺腺癌患者，按患者治疗方式不同分为化疗组(n=54)和靶向组(n=41)。化疗组患者采用一线化疗药物进行治疗，靶向组患者采用EGFR基因靶向制剂进行治疗。在完成一个周期治疗后，比较两组患者的近期疗效及治疗过程中不良反应的发生情况。对患者进行为期1年的随访，比较其生存情况。结果：(1)化疗组患者治疗后临床总有效率为92.59%(50/54)，靶向组总有效率为73.17%(30/41)，化疗组显著高于靶向治疗组(P=0.010)。(2)化疗组不良反应发生率为25.93%(14/54)，靶向治疗组则为19.51%(8/41)，组间比较差异无统计学意义(P=0.463)。(3)在随访过程中，化疗组患者有18例死亡，36例存活，患者生存率为例66.67%；靶向组患者有24例死亡，17例存活，患者生存率为41.46%，化疗组生存率显著高于靶向治疗组(P=0.014)。结论：对于EGFR基因21外显子L858R突变肺腺癌患者而言，采用化疗治疗的疗效明显优于靶向治疗，且二者安全性相当，化疗治疗的患者预后较靶向治疗者更好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of chemotherapy and targeted therapy on the clinical efficacy and survival rate of lung adenocarcinoma patients with EGFR gene 21 exon L858R mutations. Methods: A total of 95 cases of lung adenocarcinoma patients with EGFR gene 21 exon L858R mutation treated in the Chongqing Cancer Hospital from January 2012 January 2016 were divided into the chemotherapy group (n=54) and target group (n=41) according to the treatment of patients. Patients in the chemotherapy group received first-line chemotherapy, and the target group was treated with the EGFR gene targeting agent. After a cycle of treatment, the short-term efficacy and the incidence of adverse reactions during the treatment were compared between two groups. The patients were followed up for 1 year to compare their survival. Results: (1) the total effective rates of chemotherapy group and target group were 92.59% (50/54) and 73.17% (30/41), which was significantly higher in the chemotherapy group than that of the targeted therapy group (P=0.010). (2)the incidence of adverse reactions was 25.93% (14/54) in the chemotherapy group and 19.51% in the targeted therapy group (8/41). There was no significant difference between the two groups (P=0.463). (3) during follow-up, 18 cases in the chemotherapy group died, 36 cases survived, the survival rate was 66.67% cases; 24 cases in the targeted patients died, 17 cases survived, the survival rate was 41.46%, which was significantly higher than that in chemotherapy group(P=0.014). Conclusion: The curative effect of chemotherapy is obviously superior to the target chemotherapy in the treatment of lung adenocarcinoma patients with EGFR gene 21 exon L858R mutations, both methods have equal safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
